Comparison of Net Profit Growth of Pharmaceutical Issuers During the Pandemic
- A Small Font
- A Medium Font
- A Bigger Font
Most pharmaceutical companies listed on the Indonesia Stock Exchange (IDX) recorded positive performance during the first half of 2020. Merck (MERK)'s net profit growth surged 424.7% year-on-year (yoy) in the first half of 2020. Its net profit during this period was recorded at Rp 32.1 billion, up from Rp 6.1 billion.
Next was Merck Sharp (SCPI), with net profit growth of 75.7%. Then, Dharya Varia (DVLA) and Sido Muncul (SIDO) grew by 22.1% and 10.6%, respectively.
The most significant declines in net profit growth were experienced by Indofarma (INAF) and Phapros (PEHA), at -80.8% and -43.5%, respectively. Pyridam Farma (PYFA) and Kimia Farma (KAEF) also saw declines of -39% and -15.6%, respectively.
"Disclosure: This is an AI-generated translation of the original article. We strive for accuracy, but please note that automated translations may contain errors or slight inconsistencies."
Related Data
Latest Data Stories
Trending Topics
Popular Data